Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Single-Arm Open-Label Extension Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study M16-002 (1311.5)

NCT02986373 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02986373
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02986373 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Single-Arm Open-Label Extension Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study M16-002 (1311.5)
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Completed
Start date
December 15, 2016
Completion date
July 30, 2018
Enrollment
145 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

psoriatic arthritis